Yazar "Atalay, F" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Is there a relationship between olfactory dysfunction and duration of menopause?
    (PACINI EDITORE, 2025) Atalay, F; Yavuz, Z; Kars, A; Yaşar, M
    Objective. The aim of this study is to compare the odour threshold and odour identification tests of women of reproductive age and postmenopausal period and to examine the relationship between the duration of menopause and olfactory dysfunction. Methods. Eighty women of reproductive age and in the postmenopausal period were included in this prospective study. These were divided into four groups of 20 women each: Group 1, reproductive period; Group 2, postmenopausal period (0-5 years); Group 3, postmenopausal period (6-10 years); and Group 4, postmenopausal period (more than 10 years). All the women enrolled underwent complete ear, nose, and throat examinations, followed by odour threshold test and odour identification test. The results were then compared among the groups. Results. There was a statistically significant difference between the groups in terms of age, odour threshold test and odour identification test (p < 0.001, p = 0.016, and p < 0.001, respectively). Age adjusted results indicated that there were no statistically significant difference in odour threshold test scores between groups compared to the reference group 1. However, women in group 3 were 90% less likely to have higher odour & imath;dentification test scores compared to women in group 1 [OR (95% CI): 0.10 (0.01-0.73); p = 0.025]. Conclusions. Olfactory dysfunction is seen in the postmenopausal period. However, this is correlated with age. Olfactory dysfunction in the postmenopausal period appears to be the result of aging together with hormonal changes.
  • [ X ]
    Öğe
    Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients
    (SPRINGER, 2025) Küçükyurt, S; Koca, O; Demirsoy, ET; Akın, S; Doğan, A; Gören, D; Yiğitbaşı, A; Şahin, O; İpek, Y; Çiftçiler, R; Şahin, F; Mengüç, MU; Özünal, İE; Kösemehmetoğlu, ÖS; Özgür, Y; Atalay, F; Öztürk, HBA; Yüksel, M; Kanat, NT; Uysal, A; İltar, U; Yıldız, A; Karadağ, FK; Baysal, M; Uğur, MC; Güven, S; Pınar, İE; Mehtap, Ö; Barista, İ; Demir, AM; Yeral, M; Selim, C; Saydam, G; Atagündüz, İK; Tiğlioğlu, P; Dilek, İ; Ayer, M; Güneş, AK; Yüksel, MK; Ünal, A; Salim, O; Soyer, N; Ateşoğlu, EB; Eskazan, AE
    Primary mediastinal B-cell lymphoma (PMBCL) is a rare and distinct subtype of non-Hodgkin lymphoma. No consensus exists on optimal frontline treatment, and the use of R-CHOP +/- radiotherapy (RT) and DA-EPOCH-R +/- RT remains common, yet comparative real-world data are limited. In our multicenter retrospective study, we analyzed PMBCL patients, stratified by the first-line therapy (R-CHOP-21 +/- RT or DA-EPOCH-R +/- RT). Primary outcomes were complete response (CR) rate, progression-free survival (PFS), and overall survival (OS), alongside assessment of treatment-related toxicities and prognostic factors for PFS and OS. We included 157 patients [R-CHOP +/- RT group (n = 80) and DA-EPOCH-R +/- RT group (n = 77)] with a median age of 31 years, of whom 68.2% were female. CR rates were similar for R-CHOP +/- RT (75%) and DA-EPOCH-R +/- RT (76.6%). RT use was higher in the R-CHOP group (41.2% vs. 19.5%, p = 0.002). DA-EPOCH-R had significantly higher toxicity (29.9% vs. 16.2%, p = 0.033). The median follow-up of the entire cohort was 29 months with 2-year PFS and OS rates of 73.9% and 83.6%, respectively. Also, PFS and OS did not differ between regimens. In patients achieving CR with R-CHOP, RT omission did not impact survival. Multivariate analysis identified older age, poor performance status, superior vena cava syndrome and splenic involvement as independent OS predictors, while pericardial effusion, splenic involvement and hemoglobin < 10.5 g/dL were linked to inferior PFS. R-CHOP-21 +/- RT and DA-EPOCH-R +/- RT provide comparable efficacy in PMBCL. Due to the higher toxicity of DA-EPOCH-R, for those achieving CR following R-CHOP, selective RT omission may be a reasonable alternative. Established and disease-specific prognostic factors should guide individualized treatment strategies.